Over the past decade, a succession of new GvHD treatments targeting different components of the immune response have been ...

Delve into the AstraZeneca pipeline strategy in 2026 as its oncology franchise keeps growing and it invests in diversification.

Lonza discusses how navigating shorter DNA-to-IND timelines represents a key milestone in inspiring investor confidence.

Discover how GLP-1 drugs are being studied for potential new indications, from autoimmune diseases and addiction to Parkinson’s and MASH.

Find out what came out of the World Conference on Lung Cancer (WCLC) 2026, from late-stage successes and failures to earlier-stage promise.

Explore the latest oncology biotech news, from clinical data to fundraising and biotech deals, in our September 2026 roundup.

Meet Spain's biotech ecosystem at BIOSPAIN 2026 in Bilbao. Now annual, the event draws 1,000+ companies and participants from 30+ countries.

A lot is going on in the GLP-1 space in 2026, a market that landed $79 billion last year, and could shift significantly in the coming years.